Option Care Health, Inc. (OPCH)
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
- Symbol
- OPCH
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Market cap
- $3.75B
- 52 week range
- 18.01 - 36.8
Valuation
- Share price
- $23.34 (close of 2026-09-23)
- P/E (TTM)
- 18.53x
- Price to book
- 2.78x
- Price to free cash flow
- 17.65x
- Enterprise value
- $4.84B
- Book value per share
- $8.61
Price performance
| Period | Change |
|---|
| 1 day | -2.55% |
| 5 days | -0.77% |
| 1 month | -1.52% |
| 3 months | +6.24% |
| 6 months | -17.85% |
| Year to date | -26.74% |
| 1 year | -15.74% |
| 3 years | -29.89% |
| 5 years | -8.90% |
| 10 years | +105.46% |
| All time | -53.32% |
Profitability and growth
- Return on equity
- 15.65%
- Return on invested capital
- 11.09%
- Return on assets
- 6.01%
- Return on capital employed
- 12.87%
- Gross margin
- 19.26%
- Net margin
- 3.67%
- EBITDA margin
- 7.23%
- Revenue growth
- 13.03%
- Net income growth
- -2.00%
- Free cash flow growth
- -24.55%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.67%
- Current ratio
- 1.64x
- Net debt to EBITDA
- 2.70x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $5.65B
- Cost of revenue
- $4.56B
- Gross profit
- $1.09B
- EBITDA
- $408.60M
- Net income
- $207.59M
- Earnings per share
- $1.28
- Shares outstanding
- 162.10M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $5.65B | $1.09B | $207.59M | $1.28 |
| 2024-12-31 | $5.00B | $1.01B | $211.82M | $1.23 |
| 2023-12-31 | $4.30B | $981.22M | $267.09M | $1.49 |
| 2022-12-31 | $3.87B | $866.92M | $150.56M | $0.83 |
| 2021-12-31 | $3.44B | $779.61M | $139.90M | $0.78 |
| 2020-12-31 | $3.03B | $682.26M | $-8.08M | $-0.04 |
| 2019-12-31 | $2.31B | $513.00M | $-75.92M | $-0.49 |
| 2018-12-31 | $1.94B | $422.21M | $-6.12M | $-0.04 |
| 2017-12-31 | $1.83B | $446.00M | $3.88M | $0.03 |
| 2016-12-31 | $935.59M | $262.08M | $-42.77M | $-2.20 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 19.26% | 3.67% | 15.65% | 11.09% |
| 2024-12-31 | 20.27% | 4.24% | 15.08% | 11.32% |
| 2023-12-31 | 22.81% | 6.21% | 18.79% | 9.93% |
| 2022-12-31 | 22.41% | 3.89% | 10.86% | 8.23% |
| 2021-12-31 | 22.67% | 4.07% | 11.90% | 8.61% |
| 2020-12-31 | 22.50% | -0.27% | -0.80% | 5.07% |
| 2019-12-31 | 22.20% | -3.29% | -8.37% | -0.01% |
| 2018-12-31 | 21.77% | -0.32% | -1.01% | 3.46% |
| 2017-12-31 | 24.40% | 0.21% | 0.64% | 2.55% |
| 2016-12-31 | 28.01% | -4.57% | -7.12% | -1.02% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $232.62M | $1.15B |
| 2024-12-31 | $412.56M | $1.10B |
| 2023-12-31 | $343.85M | $1.06B |
| 2022-12-31 | $294.19M | $1.06B |
| 2021-12-31 | $119.42M | $1.06B |
| 2020-12-31 | $99.27M | $1.12B |
| 2019-12-31 | $67.06M | $1.28B |
| 2018-12-31 | $36.39M | $535.23M |
| 2017-12-31 | $39.46M | $502.86M |
| 2016-12-31 | $9.57M | $467.72M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $217.14M | $39.96M |
| 2024-12-31 | $287.79M | $36.14M |
| 2023-12-31 | $329.43M | $30.48M |
| 2022-12-31 | $232.19M | $16.78M |
| 2021-12-31 | $182.94M | $9.57M |
| 2020-12-31 | $100.52M | $2.92M |
| 2019-12-31 | $11.18M | $4.17M |
| 2018-12-31 | $-1.85M | $2.14M |
| 2017-12-31 | $12.91M | $1.46M |
| 2016-12-31 | $-42.54M | $1.80M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-29
- Consensus EPS estimate
- $0.44
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $0.37 |
| 2026-04-30 | - | - |
| 2026-02-24 | - | - |
| 2025-10-30 | - | - |
| 2025-07-30 | - | - |
| 2025-04-29 | - | - |
| 2025-02-26 | - | - |
| 2024-10-30 | - | - |
Filings and sources
- Company website
- optioncarehealth.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
HCA Healthcare, Inc. (HCA) · DaVita Inc. (DVA) · Universal Health Services Inc (UHS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades